Decreased expression of microRNA-214 contributes to imatinib mesylate resistance of chronic myeloid leukemia patients by upregulating ABCB1 gene expression

被引:15
|
作者
Jin, Jing [1 ]
Yao, Jia [1 ]
Yue, Fang [1 ]
Jin, Zhaoying [1 ]
Li, Dan [2 ]
Wang, Shan [1 ]
机构
[1] Jining 1 Peoples Hosp, Dept Pharm, 6 Jiankang Rd, Jining 272011, Shandong, Peoples R China
[2] Qilu Med Univ, Dept Pharm, Zibo 255213, Shandong, Peoples R China
关键词
imatinib mesylate; drug resistance; microRNA-214; P-glycoprotein; adenosine triphosphate binding cassette subfamily B member 1 gene; CHRONIC MYELOGENOUS LEUKEMIA; MULTIDRUG-RESISTANCE; P-GLYCOPROTEIN; CLINICAL-SIGNIFICANCE; EUROPEAN-LEUKEMIANET; MEDIATED EFFLUX; DOWN-REGULATION; CANCER; CELLS; MIR-214;
D O I
10.3892/etm.2018.6404
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The aim of the present study was to determine the expression of adenosine triphosphate binding cassette subfamily B member 1 (ABCB1) gene and its protein P-glycoprotein (PGP) in bone marrow mononuclear cells from chronic myeloid leukemia (CML) patients with imatinib mesylate (IM) resistance, or IM-resistant CML K562 cells. In addition, the molecular mechanism of action of microRNA (miR)-214 on ABCB1 in IM resistance was investigated. A total of 26 CML patients with IM resistance were included in the present study. In addition, 31 CML patients who did not have IM resistance were included as the control group. Bone marrow was collected from all subjects. The K562R cell line, which is a K562 cell line with IM resistance, was used for cellular studies. Reverse transcription-quantitative polymerase chain reaction was used to determine the expression of ABCB1 mRNA and miR-214 in cells. Western blotting was employed to determine the expression of PGP. Dual luciferase reporter assay was carried out to identify interactions between ABCB1 mRNA and miR-214. MTT assay was used to determine the survival rate of cells. ABCB1 mRNA and PGP expression was upregulated in bone marrow mononuclear cells from CML patients with IM resistance. K562R cells had higher ABCB1 and PGP expression than K562 cells, potentially due to their different sensitivity to IM. Expression miR-214 was decreased in bone marrow mononuclear cells from patients with IM resistance and K562R cells. Notably, miR-214 was able to bind with the 3-untranslated region, seed region of ABCB1 mRNA to regulate its expression. In addition, elevated expression of miR-214 restored IM sensitivity to K562R cells potentially by affecting ABCB1 expression. The present study demonstrated that upregulated expression of ABCB1 mRNA and PGP in bone marrow mononuclear cells from CML patients with IM resistance may be associated with the downregulation of miR-214. In addition, miR-214 may participate in the IM resistance of CML patients by regulating ABCB1 expression.
引用
收藏
页码:1693 / 1700
页数:8
相关论文
共 50 条
  • [1] Decreased Expression of microRNA-451 is Associated with Imatinib Mesylate Resistance in Chronic Myeloid Leukemia Patients
    Khalifa, Khaled
    Abbas, Omaima
    Abdlfattah, Raafat
    Alhassanin, Suzan
    Shehata, Amira
    Esawy, Sally
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S293 - S293
  • [2] ABCB1 and BMI1 mRNA expression in patients with chronic myeloid leukemia: impact on imatinib efficacy
    Bedewy, Ahmed M. L.
    Elmaghraby, Shereen M.
    Kandil, Noha S.
    BLOOD RESEARCH, 2019, 54 (01) : 57 - 62
  • [3] Gene expression signatures associated with treatment and resistance to imatinib mesylate in chronic myeloid leukemia patients.
    Oehler, V
    Branford, S
    Pogosova-Agadjanyan, E
    Shah, N
    Sawyers, C
    Mao, M
    Linsley, P
    Hughes, T
    Radich, J
    BLOOD, 2005, 106 (11) : 131A - 131A
  • [4] Molecular study of ABCB1 gene and its correlation with imatinib response in chronic myeloid leukemia
    Islem Ben Hassine
    Hanene Gharbi
    Ismail Soltani
    Hind Ben Hadj Othman
    Ahlem Farrah
    Hassiba Amouri
    Mouheb Teber
    Hela Ghedira
    Yosra Ben Youssef
    Ines Safra
    Salem Abbes
    Samia Menif
    Cancer Chemotherapy and Pharmacology, 2017, 80 : 829 - 839
  • [5] Molecular study of ABCB1 gene and its correlation with imatinib response in chronic myeloid leukemia
    Ben Hassine, Islem
    Gharbi, Hanene
    Soltani, Ismail
    Othman, Hind Ben Hadj
    Farrah, Ahlem
    Amouri, Hassiba
    Teber, Mouheb
    Ghedira, Hela
    Ben Youssef, Yosra
    Safra, Ines
    Abbes, Salem
    Menif, Samia
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 80 (04) : 829 - 839
  • [6] A gene expression signature of primary resistance to imatinib in chronic myeloid leukemia
    de Lavallade, Hugues
    Finetti, Pascal
    Carbuccia, Nadine
    Khorashad, Jamshid S.
    Charbonnier, Aude
    Foroni, Letizia
    Apperley, Jane F.
    Vey, Norbert
    Bertucci, Francois
    Birnbaum, Daniel
    Mozziconacci, Marie-Joelle
    LEUKEMIA RESEARCH, 2010, 34 (02) : 254 - 257
  • [7] MDR1/ABCB1 gene polymorphisms in patients with chronic myeloid leukemia
    Lardo, Mabel
    Castro, Marcelo
    Moiraghi, Beatriz
    Rojas, Francisca
    Borda, Natalia
    Rey, Jorge A.
    Lazarowski, Alberto
    BLOOD RESEARCH, 2015, 50 (03) : 154 - 159
  • [8] Comparative gene expression profile of chronic myeloid leukemia cells innately resistant to imatinib mesylate
    Tipping, AJ
    Deininger, MW
    Goldman, JM
    Melo, JV
    EXPERIMENTAL HEMATOLOGY, 2003, 31 (11) : 1073 - 1080
  • [9] Combined Therapy of ATRA and Imatinib Mesylate Decreases BCR-ABL and ABCB1/MDR1 Expression Through Cellular Differentiation in a Chronic Myeloid Leukemia Model
    Pinto, Camila Albuquerque
    Portilho, Adrhyann Jullyanne de Sousa
    Barbosa, Maritza Cavalcante
    De Moraes, Maria Elisabete Amaral
    De Lemos, Jose Alexandre Rodrigues
    Burbano, Rommel Mario Rodriguez
    Moreira-nunes, Caroline Aquino
    IN VIVO, 2021, 35 (05): : 2661 - 2667
  • [10] ABCB1 haplotypes but not individual SNPs predict for optimal response/failure in Egyptian patients with chronic-phase chronic myeloid leukemia receiving imatinib mesylate
    Ali, Mohamed A. M.
    Elsalakawy, Walaa Ali
    MEDICAL ONCOLOGY, 2014, 31 (11) : 1 - 10